JP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $170

Benzinga · 1d ago
JP Morgan analyst Chris Schott maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $160 to $170.